AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17456523 — intervention group
Group type: EXPERIMENTAL
Intervention: Recently diagnosed active RA patients (no prior DMARDs or corticosteroids)
Number of subjects: 381
Study 14699198 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-family group treatment
Number of subjects: 97
Study 14699198 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric outpatient care
Number of subjects: 97
Study 11434080 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational activities tailored to local needs including surgeon study groups, primary care continuing medical education conferences, administrative consensus processes, videodisc-aided patient decision making, surgical outcomes management, and generalist academic detailing over a 30-month period.
Number of subjects: 10
Study 11434080 — intervention group
Group type: COMPARATOR
Intervention: Control communities (not specified in detail).
Number of subjects: 10
Study 10993585 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) therapy
Number of subjects: 19
Study 10993585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7860811 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissuasion interventions
Number of subjects: 0
Study 7860811 — intervention group
Group type: COMPARATOR
Intervention: Various dissuasion methods
Number of subjects: 0
Study 2173435 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg once daily (4000 anti Xa U)
Number of subjects: 583
Study 2173435 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated calcic Heparin (5000 U.I. every eight hours)
Number of subjects: 583
Study 2173435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (as referenced from Turpie, Levine, et al 1986)
Number of subjects: 583
Study 73013 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of A.M.L. cells and B.C.G. given on 4 occasions early in remission
Number of subjects: 30
Study 73013 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy with killed allogeneic A.M.L. cells and Glaxo B.C.G. (Control group)
Number of subjects: 30
Study 30865109 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical endotracheal intubation
Number of subjects: 61
Study 30865109 — intervention group
Group type: COMPARATOR
Intervention: Baska Mask (LMA)
Number of subjects: 61
Study 28225297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride (CIN)
Number of subjects: 0
Study 28225297 — intervention group
Group type: COMPARATOR
Intervention: Simethicone (co-administered with CIN)
Number of subjects: 0
Study 26316154 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical posterior tibial nerve stimulation
Number of subjects: 73
Study 26316154 — intervention group
Group type: COMPARATOR
Intervention: Lateral internal sphincterotomy
Number of subjects: 73
Study 22472904 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-shift group on days off
Number of subjects: 62
Study 22472904 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-shift group on 4th consecutive day off
Number of subjects: 62
Study 22472904 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-shift group after 4th consecutive day off
Number of subjects: 62
Study 22472904 — intervention group
Group type: COMPARATOR
Intervention: Day-shift group
Number of subjects: 62
Study 21723989 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-implant bar attachment
Number of subjects: 30
Study 21723989 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-implant bar attachment
Number of subjects: 30
Study 21723989 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 independent ball attachments
Number of subjects: 30
Study 21723989 — intervention group
Group type: COMPARATOR
Intervention: Criterion-based retention scores for all treatments
Number of subjects: 30
Study 21723989 — intervention group
Group type: COMPARATOR
Intervention: Force gauge and criterion-based prosthesis stability measurements
Number of subjects: 30
Study 21723989 — intervention group
Group type: EXPERIMENTAL
Intervention: O-ring treatment
Number of subjects: 30
Study 21723989 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-implant bar treatment
Number of subjects: 30
Study 19403468 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem at 0.25 mg/kg per day (maximum of 10 mg/day)
Number of subjects: 201
Study 19403468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 19403468 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 201
Study 16146698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the rectus femoris (RF) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10
Study 16146698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the biceps femoris (BF) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10
Study 16146698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the tibialis anterior (TA) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10
Study 16146698 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic activity recorded from the gastrocnemius (GC) before exercise, at half-time and immediately after the 90-min exercise protocol
Number of subjects: 10
Study 16625136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n=130)
Number of subjects: 230
Study 16625136 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=100)
Number of subjects: 230
Study 12765594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin (heparin of low molecular weight), injected subcutaneously at 3500 IU/day for the first 10 days and 2500 IU/day up to 90 days
Number of subjects: 42
Study 12765594 — intervention group
Group type: COMPARATOR
Intervention: Physiological serum injected subcutaneously
Number of subjects: 42
Study 12765594 — intervention group
Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 42
Study 10490798 — intervention group
Group type: EXPERIMENTAL
Intervention: 189 bp homozygotes
Number of subjects: 502
Study 10490798 — intervention group
Group type: EXPERIMENTAL
Intervention: 189 bp heterozygotes
Number of subjects: 502
Study 10490798 — intervention group
Group type: EXPERIMENTAL
Intervention: non-189 bp carriers
Number of subjects: 502
Study 10490798 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1 marker
Number of subjects: 502
Study 8951932 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 250 mg i.v.
Number of subjects: 48
Study 8951932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1955637 — intervention group
Group type: EXPERIMENTAL
Intervention: SMX168-poly-L-tyrosine skin test reagent
Number of subjects: 50
Study 1955637 — intervention group
Group type: COMPARATOR
Intervention: SMX-tyrosine (monovalent reagent)
Number of subjects: 50
Study 1955637 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST assessment
Number of subjects: 50
Study 7048919 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 percent topical acyclovir ointment
Number of subjects: 180
Study 7048919 — intervention group
Group type: COMPARATOR
Intervention: Placebo, polyethylene glycol (PEG)
Number of subjects: 180
Study 31984762 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual contact group (phone calls at baseline, 6 months, and annually through 3 years)
Number of subjects: 305
Study 31984762 — intervention group
Group type: COMPARATOR
Intervention: Baseline contact group (phone call at baseline only)
Number of subjects: 305
Study 31984762 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants successfully contacted at baseline
Number of subjects: 305
Study 31984762 — intervention group
Group type: COMPARATOR
Intervention: Participants not contacted successfully at baseline
Number of subjects: 305
Study 29233473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracranial electrodes (depth and/or strip leads) implanted for brain-responsive stimulation
Number of subjects: 121
Study 27527848 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 1170
Study 27527848 — intervention group
Group type: COMPARATOR
Intervention: iGlar
Number of subjects: 1170
Study 27527848 — intervention group
Group type: COMPARATOR
Intervention: Lixi
Number of subjects: 1170
Study 25551475 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) treatment
Number of subjects: 61
Study 25551475 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 61
Study 23850491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitimagene ceradenovec (1×10^12 viral particles) followed by ganciclovir (5 mg/kg intravenously twice a day) in addition to standard care
Number of subjects: 250
Study 23850491 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 250
Study 23850491 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitimagene ceradenovec and ganciclovir
Number of subjects: 250
Study 20965380 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in physical activities as reported by 8th-grade girls
Number of subjects: 0
Study 20965380 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in organized programs
Number of subjects: 0
Study 20965380 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity trends from 6th to 8th grade
Number of subjects: 0
Study 19052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplementation (10% protein) for 21 days
Number of subjects: 42
Study 19052243 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous diet only (control group)
Number of subjects: 42
Study 16415304 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg daily)
Number of subjects: 866
Study 16415304 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE/MPA (0.625/2.5 mg daily)
Number of subjects: 866
Study 16415304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 866
Study 12571649 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat two portions of oily fish each week or take three fish oil capsules daily
Number of subjects: 3114
Study 12571649 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to eat more fruit, vegetables, and oats
Number of subjects: 3114
Study 12571649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of dietary advice (oily fish and fruit)
Number of subjects: 3114
Study 12571649 — intervention group
Group type: COMPARATOR
Intervention: No specific dietary advice
Number of subjects: 3114
Study 10618299 — intervention group
Group type: EXPERIMENTAL
Intervention: (32)P radioactive beta-emitting stents with activity level of 0.75 to 3.0 microCi (group 1)
Number of subjects: 82
Study 10618299 — intervention group
Group type: EXPERIMENTAL
Intervention: (32)P radioactive beta-emitting stents with activity level of 3.0 to 6.0 microCi (group 2)
Number of subjects: 82
Study 10618299 — intervention group
Group type: EXPERIMENTAL
Intervention: (32)P radioactive beta-emitting stents with activity level of 6.0 to 12.0 microCi (group 3)
Number of subjects: 82
Study 9199864 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES) treatment for two weeks
Number of subjects: 11
Study 9199864 — intervention group
Group type: COMPARATOR
Intervention: Control (rehabilitation only) for two weeks
Number of subjects: 11
Study 8260078 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler ultrasound intervention
Number of subjects: 4235
Study 8260078 — intervention group
Group type: COMPARATOR
Intervention: Standard obstetric management (control)
Number of subjects: 4235
Study 3978008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine 6.25 mg h‐1 infusion
Number of subjects: 98
Study 3978008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 10 ml h‐1 infusion
Number of subjects: 98
Study 3978008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 12.5 mg h‐1 infusion
Number of subjects: 98
Study 3978008 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% bupivacaine 18.75 mg h‐1 infusion
Number of subjects: 98
Study 3978008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infusion)
Number of subjects: 98
Study 29392869 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) combined with fractional CO2 laser
Number of subjects: 56
Study 29392869 — intervention group
Group type: COMPARATOR
Intervention: 595 nm PDL
Number of subjects: 56
Study 27784622 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 30
Study 27784622 — intervention group
Group type: COMPARATOR
Intervention: Sham KT (Control)
Number of subjects: 30
Study 24902020 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation in GDM group
Number of subjects: 52
Study 24902020 — intervention group
Group type: COMPARATOR
Intervention: Control group (normoglycemic women)
Number of subjects: 52
Study 22388476 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (medication or cognitive-behavioral therapy)
Number of subjects: 60
Study 22388476 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission of mothers' depression (regardless of treatment assignment)
Number of subjects: 60
Study 22388476 — intervention group
Group type: COMPARATOR
Intervention: Referral to existing community services
Number of subjects: 60
Study 19699049 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART group (technology-based weight reduction program)
Number of subjects: 111
Study 19699049 — intervention group
Group type: COMPARATOR
Intervention: Usual care group (standard nutritional program)
Number of subjects: 111
Study 18755319 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg calcium carbonate plus 400 IU vitamin D(3) per day
Number of subjects: 33067
Study 18755319 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo pills
Number of subjects: 33067
Study 15653998 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered reduced glutathione (GSH)
Number of subjects: 19
Study 15653998 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride with a hint of quinine)
Number of subjects: 19
Study 12843166 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 80
Study 12843166 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 80
Study 12843166 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 80
Study 10029341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation with F(I)O2 of 0.40
Number of subjects: 9
Study 10029341 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls) with F(I)O2 of 0.40
Number of subjects: 9
Study 10029341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation with F(I)O2 of 0.21
Number of subjects: 9
Study 10029341 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls) with F(I)O2 of 0.21
Number of subjects: 9
Study 8743187 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulation for 6 months
Number of subjects: 991
Study 8743187 — intervention group
Group type: COMPARATOR
Intervention: No anticoagulation or shorter duration
Number of subjects: 991
Study 1662562 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg once daily
Number of subjects: 12
Study 1662562 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily
Number of subjects: 12
Study 6356756 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.13 mg/kg)
Number of subjects: 60
Study 6356756 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.17 mg/kg)
Number of subjects: 60
Study 6356756 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60
Study 6356756 — intervention group
Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 60
Study 31868067 — intervention group
Group type: EXPERIMENTAL
Intervention: Vignettes depicting an individual addicted to opioids as either Black or White, male or female, and working‐ or middle‐class.
Number of subjects: 0
Study 31868067 — intervention group
Group type: EXPERIMENTAL
Intervention: Attributing addiction to bad character.
Number of subjects: 0
Study 31868067 — intervention group
Group type: EXPERIMENTAL
Intervention: User or participant gender.
Number of subjects: 0
Study 31794587 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted UKA
Number of subjects: 112
Study 31794587 — intervention group
Group type: COMPARATOR
Intervention: Conventional UKA
Number of subjects: 112
Study 29595123 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination formulation (salbutamol 4 mg and ambroxol 15 mg)
Number of subjects: 24
Study 29595123 — intervention group
Group type: COMPARATOR
Intervention: Co-administration of salbutamol 4 mg and ambroxol 15 mg
Number of subjects: 24
Study 29595123 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol 4 mg
Number of subjects: 24
Study 29595123 — intervention group
Group type: COMPARATOR
Intervention: Ambroxol 15 mg
Number of subjects: 24
Study 27919965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with docetaxel (10 mg/kg bevacizumab i.v. plus 50 mg/m2 docetaxel i.v.)
Number of subjects: 65
Study 27919965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab combined with paclitaxel (10 mg/kg bevacizumab i.v. plus 90 mg/m2 paclitaxel i.v.)
Number of subjects: 65
Study 27919965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg i.v.) alone after progression
Number of subjects: 65
Study 27919965 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab-related serious adverse events
Number of subjects: 65
Study 24838177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily for 5 days (Period 1)
Number of subjects: 0
Study 24838177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg once daily coadministered with telaprevir 750 mg every 8 h for 10 days (Period 2)
Number of subjects: 0
Study 24838177 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of dolutegravir with boceprevir or telaprevir
Number of subjects: 0
Study 24838177 — intervention group
Group type: COMPARATOR
Intervention: Historical data for boceprevir and telaprevir
Number of subjects: 0
Study 22542365 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 IU/day antithrombin (AT) supplementation for 3 days
Number of subjects: 729
Study 22542365 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 IU/day antithrombin (AT) supplementation for 3 days
Number of subjects: 729
Study 22542365 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 729
Study 19996954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of bupivacaine mixed with contrast
Number of subjects: 24
Study 19996954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml of bupivacaine mixed with contrast
Number of subjects: 24
Study 19996954 — intervention group
Group type: COMPARATOR
Intervention: Prone position
Number of subjects: 24
Study 19996954 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 24
Study 17511185 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg sufentanil and 2.5 mg bupivacaine
Number of subjects: 40
Study 17511185 — intervention group
Group type: COMPARATOR
Intervention: 25 mg tramadol and 2.5 mg bupivacaine
Number of subjects: 40
Study 15895421 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS, 15 Hz, 110% above motor threshold, 10 daily sessions)
Number of subjects: 25
Study 15895421 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 25
Study 15895421 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 25
Study 11840381 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate 4 mEq/kg/d
Number of subjects: 8
Study 11840381 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate 2 mEq/kg/d to 3 mEq/kg/d
Number of subjects: 8
Study 11840381 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (various dosages)
Number of subjects: 8
Study 10852285 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching by patient partners
Number of subjects: 80
Study 10852285 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching by rheumatology fellows
Number of subjects: 80
Study 10852285 — intervention group
Group type: COMPARATOR
Intervention: Teaching by patient partners (Group 3A)
Number of subjects: 80
Study 10852285 — intervention group
Group type: COMPARATOR
Intervention: Teaching by rheumatology trainees (Group 3B)
Number of subjects: 80
Study 8801202 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine foam enema
Number of subjects: 295
Study 8801202 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone foam enema
Number of subjects: 295
Study 1355797 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg zinc daily
Number of subjects: 57
Study 1355797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 6833501 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk reduction education program
Number of subjects: 24
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led program for comorbidities management
Number of subjects: 962
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment with NSAIDs and biologics
Number of subjects: 962
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimorbidity index assessing the number of morbid conditions
Number of subjects: 962
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 962
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease activity and mHAQ
Number of subjects: 962
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 962
Study 30025953 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity and anxiety/depression
Number of subjects: 962
Study 29558161 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training with normal body weight (JTBW)
Number of subjects: 19
Study 29558161 — intervention group
Group type: COMPARATOR
Intervention: High-repetition jump training with body weight support (JTBWS)
Number of subjects: 19
Study 26989846 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine combination tablets (bedtime administration)
Number of subjects: 0